Resigratinib
Resigratinib (KIN-3248) is an irreversible and orally active covalent inhibitor of FGFR1-4 that effectively inhibits wild-type and drug-resistant mutations (such as FGFR2 V565F, FGFR3 V555M) . Resigratinib covalently binds to the Cys492 site of FGFR, blocks the FGFR signaling pathway, inhibits tumor cell proliferation and induces apoptosis. Resigratinib can be used for the study of FGFR2/3-driven solid tumors (such as cholangiocarcinoma and bladder cancer) [1][2].
Product Specifications
CAS Number
[2750709-91-0]
Product Name Alternative
KIN-3248
UNSPSC
12352005
Target
FGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/resigratinib.html
Purity
99.53
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CNC1=C(C(N)=O)C(C#CC2=C(F)C=C(N(C3CC3)C=N4)C4=C2F)=NN1[C@H]5C[C@@H](N(C5)C(C=C)=O)COC
Molecular Formula
C26H27F2N7O3
Molecular Weight
523.53
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
FIG4, CT (FIG4, KIAA0274, SAC3, Polyphosphoinositide phosphatase, Phosphatidylinositol 3,5-bisphosphate 5-phosphatase, SAC domain-containing protein 3) (AP)
FIG4, CT (FIG4, KIAA0274, SAC3, Polyphosphoinositide phosphatase, Phosphatidylinositol 3,5-bisphosphate 5-phosphatase, SAC domain-containing protein 3) (AP)
